Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Collegium Pharma (COLL)

Collegium Pharma (COLL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,441,462
  • Shares Outstanding, K 31,611
  • Annual Sales, $ 631,450 K
  • Annual Income, $ 69,190 K
  • EBIT $ 154 M
  • EBITDA $ 321 M
  • 60-Month Beta 0.60
  • Price/Sales 2.39
  • Price/Cash Flow 3.80
  • Price/Book 5.38

Options Overview Details

View History
  • Implied Volatility 48.29% (-17.27%)
  • Historical Volatility 37.18%
  • IV Percentile 21%
  • IV Rank 30.95%
  • IV High 81.84% on 10/06/25
  • IV Low 33.26% on 08/18/25
  • Expected Move (DTE 33) 4.70 (10.31%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 329
  • Volume Avg (30-Day) 37
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 382
  • Open Int (30-Day) 318
  • Expected Range 40.90 to 50.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 2.02
  • Number of Estimates 3
  • High Estimate 2.08
  • Low Estimate 1.97
  • Prior Year 1.63
  • Growth Rate Est. (year over year) +23.93%

Price Performance

See More
Period Period Low Period High Performance
1-Month
44.51 +2.45%
on 01/05/26
50.79 -10.21%
on 12/29/25
-3.11 (-6.38%)
since 12/16/25
3-Month
32.98 +38.27%
on 10/17/25
50.79 -10.21%
on 12/29/25
+12.39 (+37.31%)
since 10/16/25
52-Week
23.23 +96.30%
on 04/10/25
50.79 -10.21%
on 12/29/25
+12.14 (+36.28%)
since 01/16/25

Most Recent Stories

More News
Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference

STOUGHTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have four poster presentations highlighting real-world data from its ADHD product,...

COLL : 45.60 (-2.77%)
3 Small-Cap Stocks We’re Skeptical Of

3 Small-Cap Stocks We’re Skeptical Of

COLL : 45.60 (-2.77%)
GES : 16.82 (-0.24%)
TKR : 93.55 (-0.19%)
Collegium Provides 2026 Financial Guidance and Business Update

– Product Revenues, Net Expected in the Range of $805 Million to $825 Million – – Jornay PM ® Net Revenue Expected in the Range of $190 Million to $200 Million – – Adjusted EBITDA*...

COLL : 45.60 (-2.77%)
3 Russell 2000 Stocks Walking a Fine Line

3 Russell 2000 Stocks Walking a Fine Line

COLL : 45.60 (-2.77%)
CVGW : 25.92 (+1.17%)
HCAT : 2.31 (-1.28%)
Collegium Announces the Closing of $980 Million Syndicated Credit Facility

STOUGHTON, Mass., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced the closing of its inaugural syndicated credit facility. The new aggregate $980 million...

COLL : 45.60 (-2.77%)
2 Reasons to Avoid COLL and 1 Stock to Buy Instead

2 Reasons to Avoid COLL and 1 Stock to Buy Instead

COLL : 45.60 (-2.77%)
3 Cash-Producing Stocks We Think Twice About

3 Cash-Producing Stocks We Think Twice About

COLL : 45.60 (-2.77%)
ROCK : 57.00 (-2.16%)
FUBO : 2.67 (+0.38%)
3 Unpopular Stocks We Find Risky

3 Unpopular Stocks We Find Risky

FCN : 178.17 (+0.34%)
COLL : 45.60 (-2.77%)
BK : 121.33 (-2.13%)
Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Collegium Pharmaceutical (NASDAQ:COLL)

Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Collegium Pharmaceutical (NASDAQ:COLL)

COLL : 45.60 (-2.77%)
1 Growth Stock Set to Flourishand 2 Facing Challenges

1 Growth Stock Set to Flourishand 2 Facing Challenges

COLL : 45.60 (-2.77%)
SBCF : 33.83 (-0.57%)
LOB : 37.60 (-0.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company's product candidate consists of COL-195, COL-196, COL-171,...

See More

Key Turning Points

3rd Resistance Point 48.31
2nd Resistance Point 47.73
1st Resistance Point 46.67
Last Price 45.60
1st Support Level 45.03
2nd Support Level 44.45
3rd Support Level 43.39

See More

52-Week High 50.79
Last Price 45.60
Fibonacci 61.8% 40.26
Fibonacci 50% 37.01
Fibonacci 38.2% 33.76
52-Week Low 23.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar